JP Morgan Chase’s TriSalus Life Sciences TLSI Stock Holding History

JP Morgan Chase’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$95.8K	Buy	20,208 +8,806	+77%	+$35K	﹤0.01%	6091
2026 Q1	$42.3K	Sell	11,402 -748	-6%	-$3.66K	﹤0.01%	6261
2025 Q4	$84.8K	Buy	12,150 +4,629	+62%	+$25.9K	﹤0.01%	5974
2025 Q3	$35K	Sell	7,521 -19	-0.3%	-$89	﹤0.01%	6341
2025 Q2	$41.1K	Buy	7,540 +7,519	+35,805%	+$40.3K	﹤0.01%	5988
2025 Q1	$116	Sell	21 -3	-13%	-$16	﹤0.01%	6858
2024 Q4	$120	Sell	24 -1	-4%	-$4	﹤0.01%	6983
2024 Q3	$115	Buy	25 +5	+25%	+$26	﹤0.01%	6981
2024 Q2	$110	Sell	20 -10,539	-100%	-$89.4K	﹤0.01%	6871
2024 Q1	$103K	Buy	+10,559	New	+$97.5K	﹤0.01%	5660
2022 Q1	–	Sell	-55,000	Closed	-$543K	–	7020
2021 Q4	$543K	Sell	55,000 -195,210	-78%	-$1.94M	﹤0.01%	4778
2021 Q3	$2.48M	Buy	250,210 +250,000	+119,048%	+$2.45M	﹤0.01%	3608
2021 Q2	$2K	Buy	+210	New	+$2.06K	﹤0.01%	6216

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

JP Morgan Chase's TLSI Position: Q2 2026 in Review

JP Morgan Chase increased its TriSalus Life Sciences (TLSI) stake by 77% in Q2 2026, buying an estimated $35K and bringing the position to 20,208 shares worth $95.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6091.

JP Morgan Chase first reported a position in TLSI in Q2 2021 and has held it in 13 quarters since. The position peaked at $2.48M in Q3 2021. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

JP Morgan Chase held 20,208 shares of TriSalus Life Sciences worth $95.8K as of Q2 2026.
JP Morgan Chase bought 8,806 TriSalus Life Sciences shares in Q2 2026, an estimated $35K.
TriSalus Life Sciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6091 holding.
JP Morgan Chase first reported a position in TriSalus Life Sciences in Q2 2021 and has held it in 13 quarters since.
JP Morgan Chase's TriSalus Life Sciences position peaked at $2.48M in Q3 2021.
79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.